CD274 and lung carcinoma: The expression of these molecules could serve as a therapeutic target, qualify for anti-PD-1 or anti-PD-L1 antibody therapy, or aid in diagnosing lung cancer [20]. Investigating biomarkers and other immune factors will influence the effectiveness of immunotherapy.